Comparison of the hypoglycemic action of Gliclazide and Glibenclamide.
スポンサーリンク
概要
- 論文の詳細を見る
We have investigated the effects of Gliclazide and Glibenclamide on glycemic control in 20 Type II diabetics. All patients were treated with a daily single dose of Glibenclamide 2.5-5.0 mg and were kept under stable glycemic control for 4 months. Using an equivalent tablet for tablet dose, the patients were then switched to Gliclazide. Each patient was seen monthly for 8 months, and the fasting plasma glucose levels (FPG), HbA<SUB>1</SUB> and HbA<SUB>1</SUB>c were recorded.<BR>During the Glibenclamide period, the patients' mean FPG (±SD) was 146±21 mg/d<I>l</I>. Switching to Gliclazide produced a significant increase in mean FPG (157 mg/d<I>l</I>, after one month and 170 mg/d<I>l</I>, after 4 months). But the HbA1 and HbAic did not change significantly throughout the observation periods. After the switch to Gliclazide, the FPG increased in 9 of the 20 patients (> 10 mg/d<I>l</I>) but the HbA<SUB>1</SUB>c increased in 4 patients (> 0.5%) and decreased in 5 patients (>0.5%).<BR>Although there is some evidence that a pharmacological difference between the 2 drug exists, our conclusion is that the hypoglycemic effects of Glibenclamide of 2.5 mg are equal to Gliclazide at 40 mg.
- 一般社団法人 日本糖尿病学会の論文
一般社団法人 日本糖尿病学会 | 論文
- Hyperlipidemia and Analysis of the Use of Lipid-lowering Drugs in Non-insulin-dependent Diabetes Mellitus.
- Thyrotoxic Crisis in a Patient with Mitochondrial Diabetes Mellitus.
- Rapidly Progressive Nephropathy in a Young Patient with Mitochondrial Gene Mutation.
- An Autopsy Case of Ketoacidosis in Insulin Dependent Diabetes Mellitus Patient Complicated with Adult Respiratory Distress Syndrome, DIC and Leukopenia.
- Studies on Alcoholic Beverages in Relation to Body Weight for Mild Diabetics